Dianthus expects ~$514M cash at year-end 2025; CEO to present at JPM conference

Dianthus Therapeutics, Inc. /DE/

Preliminary unaudited cash, cash equivalents, and short-term investments of ~$514M as of Dec 31, 2025.
Actual results may differ materially due to completion of financial closing procedures.
CEO Marino Garcia to present at 44th Annual J.P. Morgan Healthcare Conference on Jan 12, 2026.
Presentation focuses on advancing the autoimmune-focused pipeline.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.